Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. [electronic resource]
Producer: 20050119Description: 4858-64 p. digitalISSN:- 1078-0432
- Animals
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Blotting, Western
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Dose-Response Relationship, Drug
- Drug Synergism
- ErbB Receptors -- metabolism
- Fibroblast Growth Factor 2 -- biosynthesis
- Gefitinib
- Humans
- Male
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Mitogen-Activated Protein Kinases -- metabolism
- Nuclear Proteins -- genetics
- Oligonucleotides, Antisense -- pharmacology
- Phosphorylation -- drug effects
- Prostatic Neoplasms -- metabolism
- Protein Biosynthesis -- drug effects
- Protein Serine-Threonine Kinases -- metabolism
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins c-akt
- Proto-Oncogene Proteins c-mdm2
- Quinazolines -- pharmacology
- Time Factors
- Vascular Endothelial Growth Factor A -- biosynthesis
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.